Hologic Announces the Election of Dr. Arthur G. Lerner to the Company's Board of Directors

BEDFORD, Mass., Mar. 15, 2005 /PRNewswire-FirstCall/ -- Hologic, Inc. (NASDAQ: HOLX) today announced Dr. Arthur G. Lerner, was elected as a new member of the Company's Board of Directors by the stockholders at the February 28, 2005 annual stockholders meeting.

Dr. Lerner, an Armonk, New York resident, has been practicing medicine for more than thirty years and is currently in private practice as a breast surgeon. Since 1997, Dr. Lerner has also been the Surgical Director at the Dickstein Cancer Treatment Center in White Plains, New York, and an attending surgeon and past Director of Surgery at White Plains Hospital Center. Dr. Lerner has been affiliated with White Plains Hospital Center since 1974, is a past President of the Medical Staff and has served as a member of the Hospital's Board of Directors from 1986 to 1994.

A graduate of the Albert Einstein College of Medicine, in Bronx, New York, Dr. Lerner served his internship and residency in general surgery at Bronx Municipal Hospital Center - Albert Einstein College of Medicine. He has also held several teaching positions including Instructor in Surgery at Albert Einstein College of Medicine and Assistant Professor of Surgery at the University of Nebraska.

Among his professional associations, Dr. Lerner currently serves as Chairman of the Cancer Committee for the White Plains Hospital Cancer Program and Chairman of the Corporate Relations Committee for the American Society of Breast Surgeons. Dr. Lerner is a current member of the American College of Surgeons, the New York State Medical Society, the American Institute of Ultrasound in Medicine and the Metropolitan Breast Cancer Group. Dr. Lerner has previously served as President of the American Society of Breast Surgeons, President of the American College of Surgeons, Westchester Chapter, Chairman of the Westchester Academy of Medicine, Division of Surgery and Governor of the American College of Surgeons.

"We are very pleased to have Dr. Lerner join our board of directors," said Jack W. Cumming, Hologic's Chairman and Chief Executive Officer. "We believe his knowledge of the healthcare industry coupled with his clinical expertise in breast cancer will help Hologic achieve its long term growth objectives."

Hologic, Inc. is a leading developer, manufacturer and supplier of medical imaging systems dedicated to serving the healthcare needs of women, and a leading developer of state-of-the-art digital imaging technology for general radiography and mammography applications. Hologic's core business units are focused on osteoporosis assessment, mammography and breast biopsy, direct-to- digital X-ray for general radiography applications and mini C-arm imaging for orthopedic applications. For more information, please visit

Forward Looking Disclaimer

This News Release contains forward-looking information that involves risks and uncertainties, including statements about Hologic's plans, objectives, expectations and intentions. Such statements include, without limitation, statements regarding the Company's belief that Dr. Lerner's knowledge and experience will help Hologic achieve its long term growth objectives. These forward-looking statements are subject to known and unknown risks and uncertainties that could cause actual results to differ materially from those anticipated. The Company cannot assure that it will be able to benefit from Dr. Lerner's knowledge and experience or that it will be able to achieve its long term growth objectives. Factors that could cause actual results to materially differ include, without limitation, uncertainties inherent in the ability of the Company to accurately assess the skills and capabilities of Dr. Lerner; manufacturing risks that may limit the Company's ability to ramp-up commercial production of the Selenia and other of the Company's digital products, including the Company's reliance on a single source of supply for some key components of its products as well as the need to comply with especially high standards for those components and in the manufacture of digital X-ray products in general; uncertainties inherent in the development of new products and the enhancement of existing products, including technical and regulatory risks, cost overruns and delays; the risk that newly introduced products may contain undetected errors or defects or otherwise not perform as anticipated; the Company's ability to predict accurately the demand for its products, and products under development, and to develop strategies to address its markets successfully; the early stage of market development for digital X- ray products; risks relating to compliance with financial covenants under the Company's working capital financing and leases; technical innovations that could render products marketed or under development by the Company obsolete; competition; and reimbursement policies for the use of the Company's products. Other factors that could adversely affect the Company's business and prospects are described in the Company's filings with the Securities and Exchange Commission. Hologic expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in the Company's expectations or any change in events, conditions or circumstances on which any such statement is based.

   Glenn P. Muir                           Frances Crecco
   Executive Vice President and CFO        Director, Investor Relations
   Hologic, Inc.                           Hologic, Inc.
   (781) 999-7300                          (781) 999-7377

SOURCE: Hologic, Inc.

CONTACT: Glenn P. Muir, Executive Vice President and CFO,
+1-781-999-7300, or Frances Crecco, Director, Investor Relations,
+1-781-999-7377, both of Hologic, Inc.

Web site: